Average analyst price targets over $50, the drug works, the drug is FDA approved, their direct competitor was acquired with no FDA approval, and yet RLYP's stock is torched at every opportunity. I used to own this from $13 to about $19, then missed the run to $30. Now today it may open in the $14's...It can't just be because of their quarterly report...Everyone knows a new biotech has expenses to launch drugs....And Morgan Stanley's bearish thesis can't trump (no pun intended) 5 other analysts, right? What am I missing?
Well it turns out all these years most of here were correct, i.e. the Fed's strategy was wrong. The textbooks say to try the wealth effect, bring sales forward (think GM bailout, etc.), but none of this has worked. This was all clearly the best example of a "kick the can down the road" strategy, which has backfired. Maybe now they'll let the markets find their own levels, instead of QE and other addictive programs. On another note, you're were correcct IBDman, just way too early.
I think we call agree that what's really pathetic is someone who shorts a biotech with no more than about 2-$3 downside risk, vs. about $25-$30+ upside risk.
it's waiting for the FDA decision on the competitor. TBH, either way the decision goes before the end of May for ZP, I think it's a win-win for Relypsa, for several reasons.....
Rookie question, but a fair one. The stock was red the other day when the market was up over 250 points. But the last two days, the Dow tape was down over 200 two days in a row, and SWHC was green. The point is some stocks don't follow the market. On a related note, RGR's earnings were good, so this should bode well for SWHC going forward.....in fact they're already up in after hours tonight. Good luck to all.
And this is based on absolutely nothing, other than weak shorts covering. All or most of the other E&P oil/nat gas firms are not trading anywhere near this parabolic move. My best educated guess is that the stock will be back below $20 early next week. The fundamentals don't support this parabolic move.
If I were to bet on an approval and spike in stock price from here, based solely on the chart I would say there will be an issue with the FDA, i.e. no full approval. But with biotechs, it could certainly go either way. It just doesn't look like the street was expecting a full approval. Yesterday was short covering ahead of the announcement, in my opinion. So my bet is the FDA will seek more information, and the stock will fall back to the $16 range or lower.
Mrkenter....nice investment! One of the "fast traders" on CNBC owns GLNG, it was her pick for the week a few weeks ago...Huge upside....GL
I don't have enough time to explain to you what a base is...but then I'm sure you know. Cover wherever you choose, it's your money. The stock was only lower previously because the shorts only have the perception of dilution as their catalyst. And with the biotech collapse, the street built a narrative that the capital markets would be a headwind for RLYP. Nothing could be further from the truth. I don't really know why I'm wasting my time responding to short sellers.
If you're not happy which obviously you're not, then do everyone a favor and sell your shares.
Really? It's China's fault and not Apple's fault? Why can't people just embrace that their growth is over and move on?
Analysts upgrade a stock after a parabolic move like this (from $17-$23 in 4 trading days), and they downgrade a stock after a big drop.....What else is new.
This is comical, yet predictable. The hedge funds decide to run the market up to resistance before going short again, and they work with the financial media to create a supporting narrative. And now the talking heads are telling the world a bottom is in, and we're heading back to new highs for oil and the markets! LOL
They went by the Econ 101 and Fed playbook back in 2009. You bail everyone out, flood the markets with cash and liquidity, bring all sales forward (like autos, others), and then pray for the best. Well it didn't work. Sure it "worked" for 6 years, but they should have just let the markets play out on their own. Now the unwinding process is underway, and everyone is getting mauled. Yellen will tell the Senate that it worked for the USA, but they can't control China and Europe. I'd argue it didn't work for the USA.
BWLD missed their numbers badly top and bottom line last night, and guided down with a warning. Today the stock was up 7.5% or $11....I saw that DATA report, and they crushed their numbers.....Where would DATA be trading if they MISSED their numbers? Yes, it's a scam.
For the past several weeks, he said to use every rally as a selling opportunity, an opportunity to get out of your positions. Now he saying jump back into the market, this rally is for real. Is this guy for real?
And yet the stock is up from $17 to $22.40 in 3 trading days. Even though I'm under water now, I somehow feel sorry for those piling in with the short covering, thinking the worst is over and oil is heading to $50 tomorrow. I've seen this short covering movie many times....I wouldn't be surprised to CLR back below $20 early next week.
Trading over $65 after giving a revenue warning, this looks like an opportunity for the other side of the trade.
GLNG is so undervalued now. The analysts who cover the stock have new price targets averaging about $65....$65! And 1 analyst has an $80 price target. This partnership with Schlumberger is a huge validation for their business. Based on this, I would say the smart money is accumulating.
Kudos to all on the "MRK offer" thread, great read.
So my take involves an off topic look at AZN's stock chart. Yes, they just had a disappointing quarter, but the stock has been in a long term downtrend. It popped a bit right after the announced ZSPH acquisition in Nov., but since then it has resumed its downtrend in a big way. My point? If the street really thought Z's drug was anything close to a home run M&A, they (the street) would have had more respect for AZN than they do, IMHO. I realize AZN has many other irons in the game, but still... and I could be way off base here, but I follow the technicals very closely, because that's the only leading indicator we have of big money movement....It's not a perfect science, but it can be very reliable.
On the other hand, RLYP's chart is consolidating the big move to offer $25 in early April, with a typical Fibonacci retracement. BTW, it will be very easy to determine who's short or long the stock, based on the responses I get to my post.